Peripheral oxytocin is associated with reduced symptom severity in schizophrenia

Leah H. Rubin, C. Sue Carter, Lauren Drogos, Hossein Pournajafi-Nazarloo, John A. Sweeney, Pauline M. Maki

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Background: Emerging evidence from clinical trials suggests that oral estrogen and intranasal oxytocin might reduce symptom severity in schizophrenia. Whether increases in endogenous hormones are similarly associated with improved symptoms is unknown. We investigated the effects of menstrual cycle phase and related fluctuations in peripheral hormone levels on clinical symptoms in women with chronic schizophrenia. Method: Twenty-three women with schizophrenia were administered the Positive and Negative Syndrome Scale (PANSS), a measure of clinical symptom severity, at two menstrual cycle phases: 1) early follicular (Days 2-4; low estrogen/progesterone) and 2) midluteal (Days 20-22; high estrogen/progesterone). Twenty-seven males with schizophrenia and 58 controls (31 female) completed testing at comparable intervals. Men were included to examine whether the relationships between clinical symptoms and hormone levels in women generalize to men. Plasma hormone assays of estrogen, oxytocin, progesterone, and testosterone were obtained. Results: Female patients showed less severe symptoms during the midluteal versus early follicular phase (p's < 0.01). Oxytocin did not fluctuate across phases, but in female patients (p's < 0.01) higher oxytocin levels were associated with less severe positive symptoms and overall psychopathology. In both sexes, higher oxytocin levels were associated with more prosocial behaviors (p< 0.05). Conclusion: Consistent with previous findings in acutely ill patients, our results suggest that clinical symptoms vary across the menstrual cycle in patients with chronic schizophrenia. Similar to recent findings regarding benefits of intranasal oxytocin, these new findings indicate that high levels of endogenous oxytocin might improve positive symptom severity and general psychopathology in women and social behaviors in both sexes.

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalSchizophrenia Research
Volume124
Issue number1-3
DOIs
StatePublished - Dec 2010

Fingerprint

Oxytocin
Schizophrenia
Estrogens
Menstrual Cycle
Hormones
Progesterone
Psychopathology
Follicular Phase
Social Behavior
Testosterone
Clinical Trials

Keywords

  • Estrogen
  • Menstrual cycle
  • Oxytocin
  • Progesterone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Rubin, L. H., Carter, C. S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J. A., & Maki, P. M. (2010). Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophrenia Research, 124(1-3), 13-21. https://doi.org/10.1016/j.schres.2010.09.014

Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. / Rubin, Leah H.; Carter, C. Sue; Drogos, Lauren; Pournajafi-Nazarloo, Hossein; Sweeney, John A.; Maki, Pauline M.

In: Schizophrenia Research, Vol. 124, No. 1-3, 12.2010, p. 13-21.

Research output: Contribution to journalArticle

Rubin, LH, Carter, CS, Drogos, L, Pournajafi-Nazarloo, H, Sweeney, JA & Maki, PM 2010, 'Peripheral oxytocin is associated with reduced symptom severity in schizophrenia', Schizophrenia Research, vol. 124, no. 1-3, pp. 13-21. https://doi.org/10.1016/j.schres.2010.09.014
Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophrenia Research. 2010 Dec;124(1-3):13-21. https://doi.org/10.1016/j.schres.2010.09.014
Rubin, Leah H. ; Carter, C. Sue ; Drogos, Lauren ; Pournajafi-Nazarloo, Hossein ; Sweeney, John A. ; Maki, Pauline M. / Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. In: Schizophrenia Research. 2010 ; Vol. 124, No. 1-3. pp. 13-21.
@article{5632f6ba45904a0ca27d703bc7512dab,
title = "Peripheral oxytocin is associated with reduced symptom severity in schizophrenia",
abstract = "Background: Emerging evidence from clinical trials suggests that oral estrogen and intranasal oxytocin might reduce symptom severity in schizophrenia. Whether increases in endogenous hormones are similarly associated with improved symptoms is unknown. We investigated the effects of menstrual cycle phase and related fluctuations in peripheral hormone levels on clinical symptoms in women with chronic schizophrenia. Method: Twenty-three women with schizophrenia were administered the Positive and Negative Syndrome Scale (PANSS), a measure of clinical symptom severity, at two menstrual cycle phases: 1) early follicular (Days 2-4; low estrogen/progesterone) and 2) midluteal (Days 20-22; high estrogen/progesterone). Twenty-seven males with schizophrenia and 58 controls (31 female) completed testing at comparable intervals. Men were included to examine whether the relationships between clinical symptoms and hormone levels in women generalize to men. Plasma hormone assays of estrogen, oxytocin, progesterone, and testosterone were obtained. Results: Female patients showed less severe symptoms during the midluteal versus early follicular phase (p's < 0.01). Oxytocin did not fluctuate across phases, but in female patients (p's < 0.01) higher oxytocin levels were associated with less severe positive symptoms and overall psychopathology. In both sexes, higher oxytocin levels were associated with more prosocial behaviors (p< 0.05). Conclusion: Consistent with previous findings in acutely ill patients, our results suggest that clinical symptoms vary across the menstrual cycle in patients with chronic schizophrenia. Similar to recent findings regarding benefits of intranasal oxytocin, these new findings indicate that high levels of endogenous oxytocin might improve positive symptom severity and general psychopathology in women and social behaviors in both sexes.",
keywords = "Estrogen, Menstrual cycle, Oxytocin, Progesterone, Schizophrenia",
author = "Rubin, {Leah H.} and Carter, {C. Sue} and Lauren Drogos and Hossein Pournajafi-Nazarloo and Sweeney, {John A.} and Maki, {Pauline M.}",
year = "2010",
month = "12",
doi = "10.1016/j.schres.2010.09.014",
language = "English (US)",
volume = "124",
pages = "13--21",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Peripheral oxytocin is associated with reduced symptom severity in schizophrenia

AU - Rubin, Leah H.

AU - Carter, C. Sue

AU - Drogos, Lauren

AU - Pournajafi-Nazarloo, Hossein

AU - Sweeney, John A.

AU - Maki, Pauline M.

PY - 2010/12

Y1 - 2010/12

N2 - Background: Emerging evidence from clinical trials suggests that oral estrogen and intranasal oxytocin might reduce symptom severity in schizophrenia. Whether increases in endogenous hormones are similarly associated with improved symptoms is unknown. We investigated the effects of menstrual cycle phase and related fluctuations in peripheral hormone levels on clinical symptoms in women with chronic schizophrenia. Method: Twenty-three women with schizophrenia were administered the Positive and Negative Syndrome Scale (PANSS), a measure of clinical symptom severity, at two menstrual cycle phases: 1) early follicular (Days 2-4; low estrogen/progesterone) and 2) midluteal (Days 20-22; high estrogen/progesterone). Twenty-seven males with schizophrenia and 58 controls (31 female) completed testing at comparable intervals. Men were included to examine whether the relationships between clinical symptoms and hormone levels in women generalize to men. Plasma hormone assays of estrogen, oxytocin, progesterone, and testosterone were obtained. Results: Female patients showed less severe symptoms during the midluteal versus early follicular phase (p's < 0.01). Oxytocin did not fluctuate across phases, but in female patients (p's < 0.01) higher oxytocin levels were associated with less severe positive symptoms and overall psychopathology. In both sexes, higher oxytocin levels were associated with more prosocial behaviors (p< 0.05). Conclusion: Consistent with previous findings in acutely ill patients, our results suggest that clinical symptoms vary across the menstrual cycle in patients with chronic schizophrenia. Similar to recent findings regarding benefits of intranasal oxytocin, these new findings indicate that high levels of endogenous oxytocin might improve positive symptom severity and general psychopathology in women and social behaviors in both sexes.

AB - Background: Emerging evidence from clinical trials suggests that oral estrogen and intranasal oxytocin might reduce symptom severity in schizophrenia. Whether increases in endogenous hormones are similarly associated with improved symptoms is unknown. We investigated the effects of menstrual cycle phase and related fluctuations in peripheral hormone levels on clinical symptoms in women with chronic schizophrenia. Method: Twenty-three women with schizophrenia were administered the Positive and Negative Syndrome Scale (PANSS), a measure of clinical symptom severity, at two menstrual cycle phases: 1) early follicular (Days 2-4; low estrogen/progesterone) and 2) midluteal (Days 20-22; high estrogen/progesterone). Twenty-seven males with schizophrenia and 58 controls (31 female) completed testing at comparable intervals. Men were included to examine whether the relationships between clinical symptoms and hormone levels in women generalize to men. Plasma hormone assays of estrogen, oxytocin, progesterone, and testosterone were obtained. Results: Female patients showed less severe symptoms during the midluteal versus early follicular phase (p's < 0.01). Oxytocin did not fluctuate across phases, but in female patients (p's < 0.01) higher oxytocin levels were associated with less severe positive symptoms and overall psychopathology. In both sexes, higher oxytocin levels were associated with more prosocial behaviors (p< 0.05). Conclusion: Consistent with previous findings in acutely ill patients, our results suggest that clinical symptoms vary across the menstrual cycle in patients with chronic schizophrenia. Similar to recent findings regarding benefits of intranasal oxytocin, these new findings indicate that high levels of endogenous oxytocin might improve positive symptom severity and general psychopathology in women and social behaviors in both sexes.

KW - Estrogen

KW - Menstrual cycle

KW - Oxytocin

KW - Progesterone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=78249235606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249235606&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2010.09.014

DO - 10.1016/j.schres.2010.09.014

M3 - Article

C2 - 20947304

AN - SCOPUS:78249235606

VL - 124

SP - 13

EP - 21

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -